

This is only an advertisement for information purposes and not for publication, distribution or release directly or indirectly outside India. This does not constitute an offer or an invitation or a recommendation to purchase, to hold, to subscribe or sell securities and is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated March 4, 2022 read with the addendum dated March 11, 2022, (the "Letter of Offer" or "LOF") filed with the Securities and Exchange Board of India ("SEBI"), BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges").



Our Company was originally incorporated as 'Wockhardt Pharmaceuticals Limited' in Mumbai on July 8, 1999 as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Our Company received the certificate of commencement of business from the RoC on September 1, 1999. Subsequently, the name of our Company was changed to 'Wockhardt Limited' and a fresh certificate of incorporation consequent upon change of name was granted by the RoC on December 28, 1999. For details of changes in our name and the address of our registered office, please see the section entitled "General Information" on page 47 of the LOF.

Registered Office: D-4, MIDC, Chikalthana, Aurangabad 431 006, Maharashtra, India; **Tel:** +91 240 6694 444; **Corporate Office:** Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, Maharashtra, India; **Tel:** +91 22 2653 4444, **Contact Person:** Debashis Dey, Company Secretary and Compliance Officer; **E-mail:** investorrelations@wockhardt.com; **Website:** www.wockhardt.com; **Corporate Identity Number:** L24230MH1999PLC120720

PROMOTERS OF THE COMPANY: HABIL FAKHRUDDIN KHORAKIWALA AND HUMUZA CONSULTANTS

ISSUE OF UP TO 3,32,44,650 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 5.00 EACH OF THE COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ 225 PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 220 PER EQUITY SHARE) AGGREGATING TO ₹ 7,480,046,250* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF THE COMPANY IN THE RATIO OF 3 RIGHTS EQUITY SHARES FOR EVERY 10 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON WEDNESDAY, MARCH 9, 2022 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE" ON PAGE 237 OF THE LOF.

*Assuming full subscription

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

**ISSUE OPENED ON:
TUESDAY, MARCH 15, 2022**

**ISSUE CLOSES ON*
TUESDAY, MARCH 22, 2022**

*Our Board or the Capital Raising Committee will have the right to extend the Issue Period as it may determine from time to time but not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant on or after 5.00 PM on the Issue closing day and post Issue closing day.

ASBA*

Simple, Safe, Smart way of making an application - Make use of it

*Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further information, please see the section entitled "Terms of the Issue" on page 237 of the LOF.

ADDENDUM TO THE LETTER OF OFFER, THE ABRIDGED LETTER OF OFFER, THE APPLICATION FORM AND THE RIGHTS ENTITLEMENT LETTER

This addendum to the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement Letter ("Addendum") in India is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold, to subscribe or sell either entitlements or securities. This Addendum is being issued pursuant to item (4) Schedule IX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").

Eligible Equity Shareholders are requested to please note the following:

On March 19, 2022, the Company through its subsidiary, Wockhardt Bio AG entered into a supply and collaboration agreement ("Collaboration Agreement") with Serum Life Sciences Limited for the multiple supply of vaccines in the United Kingdom. Pursuant to the Collaboration Agreement, Wockhardt Bio AG and Serum Life Sciences Limited ("SLS") have entered into a profit sharing arrangement for the supply of multiple vaccines through the creation of a new fill-finish manufacturing facility, having annual production capacity of atleast 150 million doses, owned and controlled by CP Pharmaceuticals Limited in Wrexham, Wales, exclusively for the manufacturing of vaccines for SLS as identified in the Collaboration Agreement, subject to conditions specified therein.

Accordingly, the Letter of Offer (including the sections "Risk Factors", "Our Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Material Developments" beginning on pages 16, 90, 195 and 229 of the Letter of Offer, respectively), Abridged Letter of Offer, Application Form and Rights Entitlement Letter stand amended to the extent stated hereinabove. This Addendum should be read in conjunction with the Letter of Offer, Abridged Letter of Offer, Application Form and Rights Entitlement Letter as well as the previous addendum to the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement Letter issued by the Company on March 11, 2022. This Addendum shall be communicated to SEBI and the Stock Exchanges. Further, this Addendum can be accessed on the websites of: (i) our Company at www.wockhardt.com; (ii) the Registrar and at the Registrar's web-based application platform at www.linkintime.co.in; and (iii) the Lead Manager at www.ambit.co.

Investors should only rely on the information included in this Addendum, the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement Letter as well as the previous addendum to the Letter of Offer issued by the Company, while making an investment decision to invest in the Issue.

All capitalized terms used and not defined herein shall have the same meaning assigned to them in the Letter of Offer.

For **WOCKHARDT LIMITED**

On behalf of the Board of Directors

Sd/-

Debashis Dey

Company Secretary and Compliance Officer

Place: Mumbai

Date: March 20, 2022

WOCKHARDT LIMITED is proposing, subject to market conditions and other considerations, a rights issue of its Equity Shares and has in this regard filed a Letter of Offer dated March 4, 2022 with SEBI and the Stock Exchanges. The LOF is available on the website of SEBI at www.sebi.gov.in, the Stock Exchanges i.e. National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com and the website of the Lead Manager, i.e., Ambit Private Limited at https://www.ambit.co/ and on the website of Registrar i.e., www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 16 of the LOF.

This announcement does not constitute an offer of Rights Entitlements or Rights Equity Shares for sale in any jurisdiction, including the United States, and the Rights Entitlements and Rights Equity Shares may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration. Any public offering of the Rights Entitlements and the Rights Equity Shares to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, there will be no offering of the Rights Entitlements or Rights Equity Shares in the United States.